DEF: Indaptus Therapeutics Seeks Stockholder Approval for Private Placement Share Issuance and Related Party Participation

Indaptus Therapeutics, Inc. is convening a Special Meeting of Stockholders on July 25, 2025, to seek approval for the issuance of common stock underlying convertible notes and warrants from a recently closed and ongoing private placement, including participation by its CEO, to comply with Nasdaq listing rules.

Summary

• Indaptus Therapeutics, Inc. will hold a Special Meeting of Stockholders on July 25, 2025, at 10:00 a.m. Eastern time, to approve the issuance of common stock related to an ongoing private placement.
• The private placement, which initially closed on June 12, 2025, raised $2.3 million in gross proceeds and may raise up to a maximum of $5 million.
• The company is seeking approval for shares issuable upon conversion of 6% convertible notes maturing on July 28, 2026, and upon exercise of various warrants (Common Warrants, Pre-funded Warrants, and Placement Agent Warrants).
• The conversion and exercise prices are tied to 80% of the 5-day average Nasdaq closing price, subject to a maximum of $0.40, which may be below the Nasdaq Minimum Price, thus requiring stockholder approval under Nasdaq Listing Rule 5635(d).
• Stockholder approval is also sought under Nasdaq Listing Rule 5635(c) for the participation of Jeffrey Meckler, the Chief Executive Officer and Director, in the private placement, as his notes and warrants may be considered equity compensation issued at a discount.
• The Board of Directors unanimously recommends voting FOR both the Issuance Proposal and the Related Party Proposal.
• As of the Record Date, June 16, 2025, there were 16,034,444 shares of common stock outstanding and entitled to vote.

Sentiment

Score: 6

Explanation: The document is primarily procedural, seeking stockholder approval for a necessary capital raise. While the capital raise itself is positive for liquidity, the terms (potential discount, dilution, and related-party involvement) necessitate regulatory approval and introduce dilution for existing shareholders, balancing the overall sentiment to moderately positive/neutral. It's a necessary step for the company's operations.

Positives

• The company has secured initial gross proceeds of $2.3 million from a private placement, with the potential to raise up to $5 million, providing crucial capital for operations.
• The private placement includes participation from the CEO, Jeffrey Meckler, which can be interpreted as a sign of management's confidence and commitment to the company.

Negatives

• The issuance of shares upon conversion of notes and exercise of warrants will result in material dilution of existing stockholders' economic and voting interests.
• The conversion and exercise prices may be less than the Nasdaq Minimum Price, indicating the financing was done at a discount relative to recent market prices.
• The company is required to seek stockholder approval due to Nasdaq rules, implying the terms of the private placement (discounted price, related party involvement) triggered these requirements.

Risks

• Dilution: The issuance of common stock from the conversion of notes and exercise of warrants will dilute the economic and voting interests of current stockholders. The exact magnitude of dilution is uncertain due to variable conversion/exercise prices.
• Non-Approval of Proposals: If stockholders do not approve the Issuance Proposal, the convertible notes may not be converted into common stock, and the warrants will not be exercisable into common stock, potentially impacting the company's financing structure and future capital needs.
• Market Price Volatility: The conversion and exercise prices are dependent on future trading prices of the common stock, introducing uncertainty regarding the final number of shares to be issued and the extent of dilution.

Future Outlook

The document indicates the company's intention to continue offering additional convertible notes and common warrants in the private placement until a maximum of $5 million in gross proceeds is raised, subject to potential increase at the company's discretion. The conversion of notes and exercise of warrants are contingent upon stockholder approval, which will enable the full realization of the financing terms.

Management Comments

• "You are cordially invited to attend the Special Meeting of Stockholders... it is important that your shares be represented and voted at the Special Meeting. Therefore, I urge you to promptly vote and submit your proxy..." Roger J. Pomerantz, M.D., F.A.C.P., Chairman.
• "We currently intend to hold the meeting in person. However, if we determine that a change to a virtual meeting format is advisable or required, an announcement of such change will be made on the Investors page of our website... and in a Current Report on Form 8-K as promptly as practicable."
• "We ask that each stockholder evaluate the relative benefits of in-person attendance at the Special Meeting and take advantage of the ability to vote by proxy or to provide voting instructions in accordance with the voting materials that have been provided to you."

Industry Context

This filing reflects a common practice for smaller biotechnology or pharmaceutical companies like Indaptus Therapeutics to raise capital through private placements of convertible securities. Such financings are crucial for funding ongoing research and development, clinical trials, and general corporate purposes, especially when public market conditions or company stage make traditional equity offerings less favorable. The need for stockholder approval due to Nasdaq rules highlights the regulatory scrutiny on dilutive financings and related-party transactions, a standard consideration in the biotech sector where capital needs are significant and often met through complex financial instruments.

Corporate Governance

Related Party Transactions

• Jeffrey Meckler, the Chief Executive Officer and Director of Indaptus Therapeutics, Inc., is participating in the ongoing private placement by purchasing convertible notes and common warrants.
• Stockholder approval is specifically sought for the issuance of shares to Mr. Meckler under Nasdaq Listing Rule 5635(c) because his participation may be considered equity compensation issued at a discount.

Stakeholder Impact

• Shareholders: Will experience dilution of their economic and voting interests if the proposals are approved and the shares are issued. Their approval is crucial for the company to proceed with the full terms of the private placement.
• Management/Employees: The CEO's participation in the private placement aligns his interests with other investors, and the capital raise helps secure the company's financial stability, potentially benefiting employees through continued operations.
• Creditors/Investors in Private Placement: Their investment is contingent on stockholder approval for the conversion of notes and exercise of warrants into common stock, which is necessary for their full realization of the investment terms.

Next Steps

• Hold the Special Meeting of Stockholders on July 25, 2025, to vote on the Issuance Proposal and the Related Party Proposal.
• If approved, convert the convertible notes and allow exercise of warrants into common stock.
• Potentially continue offering additional notes and warrants in the private placement up to $5 million in gross proceeds.
• File a Current Report on Form 8-K with the SEC to report the final voting results after the Special Meeting.
• Stockholders intending to submit proposals for the 2026 Annual Meeting must do so by December 29, 2025 (for inclusion in proxy materials) or between February 10, 2026, and March 12, 2026 (for presentation at the meeting).

Key Dates

Recommendation

Keywords

Indaptus Therapeutics, SEC filing, DEF 14A, Proxy Statement, Special Meeting, Stockholder Approval, Private Placement, Convertible Notes, Warrants, Nasdaq Listing Rules, Dilution, Capital Raise, Corporate Governance, Jeffrey Meckler, Paulson Investment Company